Description
Testosterone cypionate 250mg
Testosterone cypionate is a slow-acting injectable ester of the primary male androgen testosterone. Testosterone also the principle anabolic hormone in men, and is the basis of comparison by which all other anabolic/androgenic steroids are judged. As with all testosterone injectables, testosterone cypionate is highly favored by athletes for its ability to promote strong increases in muscle mass and strength. It is interesting to note that while a large number of other steroidal compounds have been made available since testosterone injectables, they are still considered to be the dominant bulking agents among bodybuilders. There is little argument that these are among the most powerful mass drugs available, testosterone cypionate included.
Contents
200mg/ml Testosterone cypionate (10ml VIAL)
Chemical names
4-androsten-3-one-17beta-ol, 17beta-hydroxy-androst-4-en-3-one
Side effects
Testosterone is readily aromatized in the body to estradiol (estrogen). Elevated estrogen levels can cause side effects such as increased water retention, body fat gain, and gynecomastia. Elevated levels of testosterone are likely to produce androgenic side effects including oily skin, acne, and body/facial hair growth. Men with a geneti predisposition for hair loss (androgenetic alopecia) may notice accelerated male pattern balding. Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis.
Administration
Although active in the body for a longer time, testosterone cypionate is usually injected on a weekly basis for physique- or performance-enhancingpurposes. The usual dosage is in the range of 200-600 mg per week, taken in cycles 6 to 12 weeks in length.This level is sufficient for most users to notice exceptional gains in muscle size and strength.
Reviews
There are no reviews yet.